Cullinan Therapeutics, Inc. has a cash-rich balance sheet and no financial debt while trading at a reasonable valuation. Read ...

Investors in Cullinan Therapeutics Inc (Symbol: CGEM) saw new options become available today, for the April 2025 expiration. One of the key data points that goes into the price an option buyer is ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability ...

Three months after the resignation of Salaheddine Mezouar, the CGEM chose a new president. Mezouar, a former finance and foreign affairs minister, who was elected in May 2018, in tandem with audit ...

Taiho Oncology Inc. and Cullinan Therapeutics Inc. (NASDAQ:CGEM) shared new data on Sunday from the central nervous system (CNS) involvement cohort of the REZILIENT2 study of zipalertinib for advanced ...

Cullinan Therapeutics focuses on unaddressed or unmet needs in oncology and autoimmune conditions. In particular, Zipalertinib and CLN-978 stand out as its most promising product candidates.

Investing.com - Guggenheim initiated coverage on Cullinan Oncology Inc. (NASDAQ:CGEM) with a Buy rating and a $30.00 price target ...